[
    [
        {
            "time": "2021-08-01",
            "original_text": "贝达药业：王家炳博士处于正常工作状态，正在积极推进临床前及早期临床项目的相关工作",
            "features": {
                "keywords": [
                    "贝达药业",
                    "王家炳",
                    "临床前",
                    "早期临床",
                    "项目推进"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业：王家炳博士处于正常工作状态，正在积极推进临床前及早期临床项目的相关工作",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-01",
            "original_text": "贝达药业：今年6月埃克替尼已获批新增术后辅助治疗适应症，成为中国第一个获准用于早期肺癌患者术后辅助治疗的一代EGFR-TKI",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "术后辅助治疗",
                    "适应症",
                    "早期肺癌"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：今年6月埃克替尼已获批新增术后辅助治疗适应症，成为中国第一个获准用于早期肺癌患者术后辅助治疗的一代EGFR-TKI",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-10",
            "original_text": "贝达药业：已预约8月10日披露2021年度半年度报告",
            "features": {
                "keywords": [
                    "贝达药业",
                    "半年度报告",
                    "披露"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业：已预约8月10日披露2021年度半年度报告",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-01",
            "original_text": "贝达药业：已有两款创新药实现上市销售",
            "features": {
                "keywords": [
                    "贝达药业",
                    "创新药",
                    "上市销售"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：已有两款创新药实现上市销售",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]